Abstract: The present invention is directed to a process for the preparation of cortexolone 17?-propionate, comprising a hydrolysis reaction of an ortho-ester of formula (III) in which R is a hydrogen atom or a methyl group, in the presence of a dilute solution of acetic acid. The present invention is also directed to a hydrated crystalline form of cortexolone 17?-propionate obtained by such process.

Abstract: The present invention relates to a process for the preparation of Fulvestrant which includes recovering the by-products deriving from the oxidation of the corresponding sulfide and then subjecting the by-products to a reduction reaction in the presence of specific reducing agents.

Abstract: A process for the preparation of fulvestrant 3-boronic acid and intermediates useful for the preparation of fulvestrant 3-boronic acid according to the process are described. Fulvestrant 3-boronic acid is obtained with high purity.

Abstract: The present invention discloses a method for the purification of cysteamine or a salt thereof from polysulfuric impurities, in particular from cystamine, by treatment with dithiothreitol.

Abstract: A method for the purification of allopregnanolone is disclosed. Allopregnanolone prepared from isopregnanolone contains impurities such as triphenylphosphine oxide and other unknown impurities. To remove these impurities and purify allopregnanolone, the allopregananolone is dissolved in acetonitrile, and crystallized from the acetonitrile. The resulting crystallized allopregnanolone may then be re-crystallized from acetonitrile to further purify the allopregnanolone.

Abstract: The present invention relates to a method for the preparation of allopregnanolone with a high degree of purity which, eventually, occurs through the formation of 3?-trifluoroacetoxy-5?-pregnan-20-one.

Abstract: A method for the purification and preparation of melphalan that allows to obtain melphalan with purity higher than 99.5% is described.

Abstract: A process for the preparation of nucleosides, derivatives and analogues thereof by coupling reaction of a protected suitable nitrogeneous purine or pyrimidine base, a derivative or analogue thereof and a protected suitable sugar in the presence of SnCl4 comprising the removal of SnCl4 by adding DMSO directly into the reaction mixture is described. Preferably said process is used for the preparation of antiviral and antitumor agents having a nucleoside or nucleoside-like structure, still more preferably for the preparation of azacytidine, decitabine, chlorfarabine, cladribine, mizoribine. A residual tin content lower than 300 ppm is obtained with said process.

Abstract: A process for the preparation of nucleosides, derivatives and analogues thereof by coupling reaction of a protected suitable nitrogeneous purine or pyrimidine base, a derivative or analogue thereof and a protected suitable sugar in the presence of SnCl4 comprising the removal of SnCl4 by adding DMSO directly into the reaction mixture is described. Preferably said process is used for the preparation of antiviral and antitumor agents having a nucleoside or nucleoside-like structure, still more preferably for the preparation of azacytidine, decitabine, chlorfarabine, cladribine, mizoribine. A residual tin content lower than 300 ppm is obtained with said process.

Abstract: A process for the preparation of neuromuscular blocking agents with isoquinoline structure, such as atracurium besylate, doxacurium chloride, mivacurium chloride and gantacurium chloride, by chromatographic purification of their mixtures of isomers using a silica modified by treatment with a tertiary amine of formula NR1R2R3 or a corresponding quaternary ammonium compound N+R1R2R3R4X? wherein R1, R2, R3 and R4, the same or different, are linear or branched C1-C4 alkyl groups or —CH2—Ar groups or two among R1, R2, R3 and R4 form a 5- or 6-membered cycle, optionally substituted with a —CH2—Ar group or condensed with an Ar group, Ar being an aryl optionally substituted with one or more electrodonating groups, and X? being a suitable anion, is described.

Abstract: A process for preparing the [R—[R*,R*-(E)]]-2,2?-(1,8-dioxo-4-octene-1,8-diyl) bis(oxy-3,1-propanediyl)bis(1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl) methyl]isoquinolinium) dichloride, commonly known as mivacurium chloride, useful as short-duration neuromuscular blocking agent.

Abstract: A stereoselective and enrichment process for the preparation of ciclesonide is described.

Abstract: A process for the preparation of neuromuscular blocking agents with isoquinoline structure, such as atracurium besylate, doxacurium chloride, mivacurium chloride and gantacurium chloride, by chromatographic purification of their mixtures of isomers using a silica modified by treatment with a tertiary amine of formula NR1R2R3 or a corresponding quaternary ammonium compound N+R1R2R3R4X? wherein R1, R2, R3 and R4, the same or different, are linear or branched C1-C4 alkyl groups or —CH2—Ar groups or two among R1, R2, R3 and R4 form a 5- or 6-membered cycle, optionally substituted with a —CH2—Ar group or condensed with an Ar group, Ar being an aryl optionally substituted with one or more electrodonating groups, and X? being a suitable anion, is described.